Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.5%. By the end of trading, Regeneron Pharmaceuticals rose $7.22 (2.4%) to $312.87 on heavy volume. Throughout the day, 1,043,622 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 692,900 shares. The stock ranged in a price between $301.97-$319.83 after having opened the day at $304.59 as compared to the previous trading day's close of $305.65. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 93.1%, Zalicus ( ZLCS), up 23.7%, Bacterin International Holdings ( BONE), up 11.6% and Delcath Systems ( DCTH), up 9.6%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.5 billion and is part of the health care sector. Shares are up 72.5% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, China Botanic Pharmaceutical ( CBP), down 96.4%, Achillion Pharmaceuticals ( ACHN), down 58.3%, Mast Therapeutics ( MSTX), down 40.1% and Cellular Dynamics International ( ICEL), down 14.3% , were all laggards within the drugs industry with Amgen ( AMGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Starbucks Slides After 'Unacceptable' Performance Leads to U.S. Store Closures

Starbucks Slides After 'Unacceptable' Performance Leads to U.S. Store Closures

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI